ClinicalTrials.gg
RecruitingNCT06771583BIOUpdated May 7, 2026

Identification and Validation of Epigenetic Biomarkers of PMDD

An observational study in PMDD, Premenstrual Dysphoric Disorder (PMDD) and Premenstrual Syndrome-PMS, sponsored by Johns Hopkins University. Recruiting at 1 site in United States. Open to female participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-07.

Sponsored by Johns Hopkins University · Observational

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
500
Ages
18 Years to 50 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Premenstrual Dysphoric Disorder with a site in United States — 4 open to participants now, 4 under way, none of them phase 3. Premenstrual Dysphoric Disorder · United States.

Started
2025
with 1 other
Observational
3 of 19
2 open now
Registered
17th of 19
by date
Lead sponsor
2 of 19
Johns Hopkins University

Among the 19 studies in Premenstrual Dysphoric Disorder with a site in United States, this one is one of 2 that started in 2025, is one of 3 observational ones, and was the 17th registered.

Premenstrual Dysphoric Disorder

42 studies on the registry are indexed under Premenstrual Dysphoric Disorder; 10 are open to participants now.

Browse Premenstrual Dysphoric Disorder studies →

Open to participants now

4 of the 19 studies in Premenstrual Dysphoric Disorder with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 7 Premenstrual Dysphoric Disorder studies recruiting now, 1 sets no upper age limit and 6 stop at 75 or younger; none take children under 18; 4 take healthy volunteers.

This study: 18 Years to 50 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Premenstrual Dysphoric Disorder with a site in United States, or all of them as a file.
02

Study summary

This research is being done to examine epigenetic markers and mood changes across the menstrual cycle, particularly in premenstrual dysphoric disorder (PMDD). The investigators previously identified epigenetic biomarkers of postpartum depression, another reproductive affective disorder, and in this study aim to determine if these biomarkers also distinguish PMDD cases from healthy controls at different points in the menstrual cycle. By collecting biological samples (such as blood) and monitoring mood changes across the menstrual cycle, the investigators will be able to determine whether these epigenetic markers are associated with PMDD. The investigators plan to study these epigenetic markers during the follicular phase (roughly the first half of the menstrual cycle, from menses until ovulation) and the luteal phase (roughly the second half of the menstrual cycle, from ovulation to menses). The investigators will study this in two groups: 1) individuals who do NOT have premenstrual mood symptoms, and 2) individuals with premenstrual syndrome/premenstrual dysphoric disorder (PMS/PMDD). The results will provide a comprehensive view of the changes in these systems across the menstrual cycle. This will add to the investigators understanding of the mechanisms that may cause PMS/PMDD.

Read the detailed description

Premenstrual dysphoric disorder (PMDD) is a reproductive affective disorder with impairing mood symptoms that emerge monthly in the premenstrual (luteal) phase of the menstrual cycle. Reproductive affective disorders, including PMDD and postpartum depression, can be conceptualized as disorders of hormone sensitivity - an abnormal brain response to ovarian hormone fluctuations. Epigenetic variations in prior studies by the investigators were prospectively predictive of postpartum depression risk with over 80% accuracy. Recently, in a cross-sectional cohort of 50 women with and without PMDD, this postpartum depression epigenetic biomarker distinguished PMDD cases from controls in the luteal phase, suggesting this may indicate sensitivity to reproductive hormone change. The primary aim of this study is to explore whether this epigenetic biomarker is a broad marker for hormone sensitivity, by assessing women (controls, PMDD) in both the follicular and luteal phases of the participant's menstrual cycles, using a repeated measures approach. A secondary aim is to examine whether the epigenetic biomarkers differ between women with PMDD who have responded to selective serotonin reuptake inhibitor (SSRI) treatment versus those who have failed SSRIs. SSRIs are the first-line treatment for PMDD, yet many PMDD patients do not respond to SSRIs. This study will assess DNA methylation in a cohort of women with PMDD and controls. The investigators will compare the epigenetic biomarker between controls and PMDD in the follicular and luteal phases. Within the PMDD group, the investigators will compare the biomarker between those who have responded to SSRI treatment and those who have not. Blood will be collected at home by participants using a dried blood spot collection system.

03

Conditions studied

  • PMDD
  • Premenstrual Dysphoric Disorder (PMDD)
  • Premenstrual Syndrome-PMS
  • Premenstrual Syndrome
  • Menstrual Cycle

Keywords

  • menstrual cycle
  • pms
  • luteal phase
  • womens health
  • reproductive health
  • reproductive mental health
  • epigenetics
  • dna methylation
  • premenstrual
  • pmdd
  • women
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Participants will be recruited from Virginia, Washington DC, and Maryland (Baltimore area).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • female sex
  • regular menstrual cycles (24-35 days)
  • age 18-50 years
  • ability to give written

Exclusion criteria

Exclusion Criteria:

  • psychiatric medication use in the past 2 months;
  • substance use disorder in the past 2 months (per MINI);
  • lifetime history of psychotic disorder including schizophrenia, schizoaffective disorder, major depression with psychotic features (per MINI);
  • history of psychiatric disorder other than PMDD in past year (per MINI);
  • active suicidal ideation with plan or attempt in past 6 months (per MINI);
  • hormone or hormonal use (except levonorgestrel as emergency contraceptive) in past 2 months;
  • pregnancy in past 6 months;
  • history of brain injury;
  • current or history of endocrine disorder including uncontrolled diabetes or thyroid disease;
  • >40.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
500 participants (estimated)
Target follow-up
3 Months
Patient registry
Yes

Groups and cohorts

  • Control

    Eligible participants that pass inclusion and exclusion criteria who do not have premenstrual mood symptoms.

  • Premenstrual Dysphoric Disorder (PMDD)

    Eligible participants that pass inclusion and exclusion criteria who do have premenstrual mood symptoms. Symptoms must be severe enough to meet PMDD criteria.

06

What researchers measure

Primary outcomes

  1. Presence of DNA Methylation Biomarkers (Comparing individuals with PMDD and controls)

    In the luteal phase, DNA methylation variations at HP1BP3, TTC9B will distinguish controls from individuals with PMDD. In the follicular phase, DNA methylation variations at HP1BP3 and TTC9B will not distinguish controls from PMDD. The investigators will be collecting dried blood spots and assaying these epigenetic markers using various DNA methylation techniques.

    Time frame: From enrollment until study completion (approximately 3 months)

Secondary outcomes

  1. Presence of DNA Methylation Biomarkers (comparing history of SSRI treatment vs SSRI non response)

    In the luteal phase, DNA methylation variations at HP1BP3, TTC9B will distinguish those with a history of SSRI treatment response versus SSRI non-response among women with PMDD. In the follicular phase, DNA methylation variations at HP1BP3, TTC9B will not distinguish those with a history of SSRI treatment response versus SSRI non-response among women with PMDD. Samples from which these assays are performed are from dried blood spots.

    Time frame: From enrollment until study completion (approximately 3 months)

  2. Epigenetic biomarkers associated with PMDD

    Novel epigenetic biomarkers associated with PMDD will be identified using dried blood spots and associated methods and techniques for analysis.

    Time frame: From enrollment until study completion (approximately 3 months)

07

Study locations

1 of 1 sites recruiting
  • Johns Hopkins Reproductive Mental Health Center
    Baltimore, Maryland 21205, United States
    Recruiting
    • Liisa Hantsoo, Ph.D. · Contactlhantso1@jhmi.edu · 215-435-3171
    • Victoria Seo, B.S. · Contactvseo1@jh.edu · 302-464-8320‬
    • Liisa Hantsoo, Ph.D. · Principal investigator
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2025 (actual). Primary completion is estimated for Feb 2030, 53 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2025
First posted
Jan 13, 2025
StartActual
Sep 12, 2025
Primary completionEst.
Feb 15, 2030
CompletionEst.
Feb 15, 2031
Last update
May 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06771583
Responsible party
Sponsor
First posted
Jan 13, 2025
Start date
Sep 12, 2025
Primary completion
Feb 15, 2030 (estimated)
Completion
Feb 15, 2031 (estimated)
Last update
May 7, 2026

Study contacts

Victoria Seo, B.S.
Contact
vseo1@jh.edu
302-464-8320‬
Victoria Paone, B.S.
Contact
vpaone1@jh.edu
Liisa Hantsoo, Ph.D.
principal investigator · Johns Hopkins University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion